Biosimilars Can't Circumvent BPCIA With Litigation
The United States District Court for the Northern District of California ruled on Nov. 12, 2013, that a party seeking to obtain approval of a biosimilar could not avoid the process...To view the full article, register now.
Already a subscriber? Click here to view full article